Jagrutiben Patel
Family · Americus, GANPI 1629566989
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by GSK at 26.3% of the total. Reporting peaked in 2021 at $934 and has fallen 81.3% since, to $175 in 2024.
Across 129 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$555
- Novo Nordisk$509
- Lilly USA, LLC$146
- Boehringer Ingelheim$131
- AstraZeneca$128
- AbbVie$103
- plus $541 from 16 others
What the payments were for
- Food & beverage$2,114100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 32 | $555 |
| Novo Nordisk | 32 | $509 |
| Lilly USA, LLC | 10 | $146 |
| Boehringer Ingelheim | 7 | $131 |
| AstraZeneca | 9 | $128 |
| AbbVie | 6 | $103 |
| Biohaven Pharmaceuticals, Inc. | 4 | $79 |
| Novartis | 3 | $57 |
| Genentech USA, Inc. | 5 | $54 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Redhill Biopharma Inc. | 2 | $42 |
| Dexcom, Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Amgen | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Exact Sciences | 1 | $18 |
| Pfizer | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Merck | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$2,114 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 28 | $21,265 |
| TrulicityDulaglutide | 11 | $12,512 |
| EliquisApixaban | 13 | $8,755 |
| Gabapentin | 56 | $613 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $417 |
| Atorvastatin Calcium | 63 | $291 |
| Amlodipine Besylate | 84 | $253 |
| Omeprazole | 27 | $250 |
| Buspirone Hcl | 24 | $230 |
| Losartan Potassium | 42 | $194 |
| Famotidine | 21 | $167 |
| Fluticasone Propionate | 13 | $142 |
| Naproxen | 13 | $142 |
| Pantoprazole Sodium | 23 | $139 |
| Hydrochlorothiazide | 49 | $134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $131 | $21,26528 claims |
| Lilly USA, LLCTrulicity | $146 | $12,51211 claims |
| PfizerEliquis | $17 | $8,75513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.
Other family in Americus
- Allie McAllisterMarietta$299K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
- Julia ThorneCanton$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.